MEDVi QUAD Formula Update Confirmed for 2026: Apomorphine Replaces PT-141 in Current 4-in-1 Combination

Sildenafil, Tadalafil, Apomorphine, and L-Citrulline Confirmed as MEDVi's Current QUAD Formulation for Compounded ED Treatment

Newark, DE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Compounded medications are not FDA-approved finished drug products. MEDVi connects patients with licensed healthcare providers who independently evaluate eligibility for treatment. Always consult a qualified healthcare professional before starting any prescription treatment.

MEDVi has confirmed the current formulation of its QUAD sublingual prescription treatment for erectile dysfunction: sildenafil, tadalafil, apomorphine, and L-citrulline, combined in a single compounded dose. The confirmation is part of a broader MEDVi product update that replaces PT-141 with apomorphine in the formula's current version.

MEDVi Confirms 2026 QUAD Formula Change

MEDVi has issued a product update confirming that its QUAD formulation now lists apomorphine in place of PT-141. The update instructs MEDVi's approved partners to review any existing placements that still reference PT-141 or an earlier QUAD ingredient list and to bring them in line with the current formula going forward.

Current MEDVi QUAD Ingredients

MEDVi's current product information identifies four components in the QUAD formulation: sildenafil, tadalafil, apomorphine, and L-citrulline. Sildenafil and tadalafil remain part of the formula as before. Apomorphine is the ingredient MEDVi's update identifies in place of PT-141, and L-citrulline continues to appear as the fourth listed component.

Sildenafil and tadalafil are prescription medications also available as individually FDA-approved finished drug products for certain indications; their presence within a compounded formulation does not make the finished QUAD combination FDA-approved. MEDVi identifies apomorphine as the component replacing PT-141 in the current formula, while L-citrulline remains listed as the fourth component.

PT-141 Replaced by Apomorphine in the Updated Formula

The change MEDVi has confirmed for 2026 is straightforward: apomorphine now appears where PT-141 previously did. Sildenafil, tadalafil, and L-citrulline are unchanged and remain listed in the current four-component formula. MEDVi's own current product page reflects this same combination, showing apomorphine, sildenafil, tadalafil, and L-citrulline as the ingredients in QUAD.

How the Updated MEDVi QUAD Formula Differs From Earlier 2026 Product Information

Earlier QUAD information may list sildenafil, tadalafil, PT-141, and L-citrulline. MEDVi's current 2026 update replaces PT-141 with apomorphine, resulting in the current listed combination of sildenafil, tadalafil, apomorphine, and L-citrulline. Previously published product information may therefore differ from current MEDVi materials depending on when it was published.

Current QUAD Sublingual Prescription Format

QUAD is dispensed as a sublingual dose that dissolves under the tongue rather than as a swallowed tablet. MEDVi states that fulfillment occurs following prescription approval. As a compounded medication, QUAD is prepared pursuant to a prescription rather than reviewed by FDA as an approved finished drug product.

MEDVi Telehealth Evaluation Process

MEDVi provides access to QUAD through a telehealth process that includes an online intake questionnaire and a review by a licensed healthcare provider before a prescription may be issued. Approved patients receive their medication by mail. Questions about drug interactions, existing medications, or individual eligibility should be directed to the prescribing provider as part of that evaluation, since suitability for treatment is a clinical determination made on a patient-by-patient basis.

Compounded Medication Status

QUAD is a compounded prescription medication. Compounded drugs are not FDA-approved finished drug products and do not undergo FDA premarket review for safety, effectiveness, or quality in the same manner as FDA-approved finished drugs.

Consumers Reviewing Earlier MEDVi QUAD Information

Because QUAD's formulation has changed more than once, older webpages, product descriptions, and previously published coverage may list an earlier ingredient combination that references PT-141 rather than apomorphine. Material published before MEDVi's most recent update reflects the formula as it stood at that time.

About MEDVi

MEDVi is a telehealth company offering QUAD, a compounded prescription treatment, through an online evaluation and licensed-provider review process. Consumers reviewing the current formulation and prescribing process can reference MEDVi QUAD official product information.

Contact Information

Email: hello@medvi.org
Phone: +1-585-312-4226
Address: 131 Continental Dr. Ste 305, Newark, DE 19713, USA

These statements have not been evaluated by the Food and Drug Administration. No FDA clearance, approval, or authorization was confirmed in the materials reviewed for this release; this release does not independently classify QUAD under FDA medical-device or drug-approval regulations, and QUAD, as a compounded medication, is not an FDA-approved finished drug product.

QUAD™ is a trademark of MEDVi. Other trademarks referenced are the property of their respective owners. Mention of these trademarks does not imply affiliation, endorsement, or sponsorship beyond what is expressly disclosed.

Additional previously published MEDVi coverage is available below.

MEDVi QUAD online provider evaluation and prescription process coverage

MEDVi telehealth provider evaluation and pricing information coverage

Email: hello@medvi.org
Phone: +1-585-312-4226